Home Other Building Blocks Prucalopride succinate

Prucalopride succinate

CAS No.:
179474-85-2
Catalog Number:
AG00270U
Molecular Formula:
C22H32ClN3O7
Molecular Weight:
485.9584
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
5mg
95%
In Stock USA
United States
$51
- +
10mg
95%
In Stock USA
United States
$78
- +
50mg
95%
In Stock USA
United States
$130
- +
100mg
95%
In Stock USA
United States
$201
- +
250mg
95%
In Stock USA
United States
$314
- +
Product Description
Catalog Number:
AG00270U
Chemical Name:
Prucalopride succinate
CAS Number:
179474-85-2
Molecular Formula:
C22H32ClN3O7
Molecular Weight:
485.9584
MDL Number:
MFCD00948731
IUPAC Name:
4-amino-5-chloro-N-[1-(3-methoxypropyl)piperidin-4-yl]-2,3-dihydro-1-benzofuran-7-carboxamide;butanedioic acid
InChI:
InChI=1S/C18H26ClN3O3.C4H6O4/c1-24-9-2-6-22-7-3-12(4-8-22)21-18(23)14-11-15(19)16(20)13-5-10-25-17(13)14;5-3(6)1-2-4(7)8/h11-12H,2-10,20H2,1H3,(H,21,23);1-2H2,(H,5,6)(H,7,8)
InChI Key:
QZRSNVSQLGRAID-UHFFFAOYSA-N
SMILES:
OC(=O)CCC(=O)O.COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(c2c1OCC2)N
UNII:
4V2G75E1CK
Properties
Complexity:
538  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
2  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
485.193g/mol
Formal Charge:
0
Heavy Atom Count:
33  
Hydrogen Bond Acceptor Count:
9  
Hydrogen Bond Donor Count:
4  
Isotope Atom Count:
0
Molecular Weight:
485.962g/mol
Monoisotopic Mass:
485.193g/mol
Rotatable Bond Count:
9  
Topological Polar Surface Area:
151A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
Literature
Title Journal
Pharmacokinetics of single and repeated oral doses prucalopride in healthy Chinese volunteers. International journal of clinical pharmacology and therapeutics 20121101
Prucalopride: evaluation of the pharmacokinetics, pharmacodynamics, efficacy and safety in the treatment of chronic constipation. Expert opinion on drug metabolism & toxicology 20121001
The use of Resolor (prucalopride) for chronic constipation in women. British journal of nursing (Mark Allen Publishing) 20120901
The successful treatment of acute refractory pseudo-obstruction with prucalopride. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland 20120801
Recent advances in the management of difficult constipation. Current gastroenterology reports 20120801
The 5-hydroxytryptamine4 receptor agonists prucalopride and PRX-03140 increase acetylcholine and histamine levels in the rat prefrontal cortex and the power of stimulated hippocampal θ oscillations. The Journal of pharmacology and experimental therapeutics 20120601
Study of the regulation of the inotropic response to 5-HT4 receptor activation via phosphodiesterases and its cross-talk with C-type natriuretic peptide in porcine left atrium. Naunyn-Schmiedeberg's archives of pharmacology 20120601
Inotropic effects of prokinetic agents with 5-HT(4) receptor agonist actions on human isolated myocardial trabeculae. Life sciences 20120409
The facilitating effect of prucalopride on cholinergic neurotransmission in pig gastric circular muscle is regulated by phosphodiesterase 4. Neuropharmacology 20120401
Prucalopride in a case of severe opioid induced constipation. Minerva anestesiologica 20120401
Assessment of the cardiac safety of prucalopride in healthy volunteers: a randomized, double-blind, placebo- and positive-controlled thorough QT study. British journal of clinical pharmacology 20120201
Randomised clinical trial: the efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction--a double-blind, placebo-controlled, cross-over, multiple n = 1 study. Alimentary pharmacology & therapeutics 20120101
In-vitro acetylcholine release is not a straightforward model to study hippocampal 5-HT₄ receptors. Neuroreport 20111207
Chronic constipation: current treatment options. Canadian journal of gastroenterology = Journal canadien de gastroenterologie 20111001
Investigation of neurogenic excitatory and inhibitory motor responses and their control by 5-HT(4) receptors in circular smooth muscle of pig descending colon. European journal of pharmacology 20110930
Estimating the relationship between preference-based generic utility instruments and disease-specific quality-of-life measures in severe chronic constipation: challenges in practice. PharmacoEconomics 20110801
[Treatment of severe chronic constipation: differential roles of conventional laxatives and the prucalopride prokinetic]. Zeitschrift fur Gastroenterologie 20110801
What role for prucalopride in constipation? Drug and therapeutics bulletin 20110801
Development and validation of a sample stabilization strategy and a UPLC-MS/MS method for the simultaneous quantitation of acetylcholine (ACh), histamine (HA), and its metabolites in rat cerebrospinal fluid (CSF). Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110715
Prucalopride for the treatment of women with chronic constipation in whom standard laxative regimens have failed to provide adequate relief. Health technology assessment (Winchester, England) 20110501
Prucalopride. In chronic constipation: poorly documented risks. Prescrire international 20110501
Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis. Gut 20110201
[New treatment option for women with chronic constipation - prucalopride stimulates the disturbed gut motility again]. Zeitschrift fur Gastroenterologie 20110101
[Prucalopride - oral (Resolor)]. Journal de pharmacie de Belgique 20101201
Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation - follow-up of patients from the pivotal studies. Alimentary pharmacology & therapeutics 20101101
Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation. Digestive diseases and sciences 20101001
A double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20100901
[New drugs for the treatment of constipation]. Medizinische Klinik (Munich, Germany : 1983) 20100701
Influence of 5-HT4 receptor activation on acetylcholine release in human large intestine with endometriosis. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20100501
Psychometric performance and clinical meaningfulness of the Patient Assessment of Constipation-Quality of Life questionnaire in prucalopride (RESOLOR) trials for chronic constipation. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20100201
Prucalopride for constipation. Expert opinion on pharmacotherapy 20100201
Selective serotonin reuptake inhibitors potentiate the rapid antidepressant-like effects of serotonin4 receptor agonists in the rat. PloS one 20100101
Investigations into the binding affinities of different human 5-HT4 receptor splice variants. Pharmacology 20100101
Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20091201
Translating 5-HT receptor pharmacology. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20091201
Prucalopride for chronic constipation. Drugs of today (Barcelona, Spain : 1998) 20091201
Prucalopride: a new drug for the treatment of chronic constipation. Expert review of gastroenterology & hepatology 20090801
Motility: prucalopride for chronic constipation. Nature reviews. Gastroenterology & hepatology 20090601
The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation. Advances in therapy 20090501
Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 20090301
Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study. Alimentary pharmacology & therapeutics 20090201
Selective desensitization of the 5-HT4 receptor-mediated response in pig atrium but not in stomach. British journal of pharmacology 20090101
Prucalopride. Drugs 20090101
New treatments for irritable bowel syndrome in women. Women's health (London, England) 20081101
Management of constipation in the elderly: emerging therapeutic strategies. World journal of gastroenterology 20080907
Alternative splicing and exon duplication generates 10 unique porcine 5-HT 4 receptor splice variants including a functional homofusion variant. Physiological genomics 20080612
A placebo-controlled trial of prucalopride for severe chronic constipation. The New England journal of medicine 20080529
The long and short of a constipation-reducing medication. The New England journal of medicine 20080529
Prucalopride and donepezil act synergistically to reverse scopolamine-induced memory deficit in C57Bl/6j mice. Behavioural brain research 20080305
5-HT4 receptor agonists increase sAPPalpha levels in the cortex and hippocampus of male C57BL/6j mice. British journal of pharmacology 20070401
The action of the novel gastrointestinal prokinetic prucalopride on the HERG K+ channel and the common T897 polymorph. European journal of pharmacology 20070112
5HT4 agonists inhibit interferon-gamma-induced MHC class II and B7 costimulatory molecules expression on cultured astrocytes. Journal of neuroimmunology 20061001
5-HT4 receptor agonists enhance both cholinergic and nitrergic activities in human isolated colon circular muscle. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20060901
Porcine left atrial and sinoatrial 5-HT(4) receptor-induced responses: fading of the response and influence of development. British journal of pharmacology 20060101
5-HT4 receptors located on cholinergic nerves in human colon circular muscle. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20050601
Prucalopride is a partial agonist through human and porcine atrial 5-HT4 receptors: comparison with recombinant human 5-HT4 splice variants. Naunyn-Schmiedeberg's archives of pharmacology 20050601
Frontocortical 5-HT4 receptors exert positive feedback on serotonergic activity: viral transfections, subacute and chronic treatments with 5-HT4 agonists. Biological psychiatry 20050415
Electrophysiological effects of prucalopride, a novel enterokinetic agent, on isolated atrial myocytes from patients treated with beta-adrenoceptor antagonists. The Journal of pharmacology and experimental therapeutics 20050401
Modulation of hippocampal excitability by 5-HT4 receptor agonists persists in a transgenic model of Alzheimer's disease. Neuroscience 20040101
Effect of enterokinetic prucalopride on intestinal motility in fast rats. World journal of gastroenterology 20030915
Gastrointestinal motility disorders and gastrointestinal prokinetic therapy. The Veterinary clinics of North America. Small animal practice 20030901
Irritable bowel syndrome: an overview of diagnosis and pharmacologic treatment. Cleveland Clinic journal of medicine 20030601
Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial. Digestion 20030101
5-HT4 receptors exert a frequency-related facilitatory control on dorsal raphé nucleus 5-HT neuronal activity. The European journal of neuroscience 20020901
Prucalopride, a systemic enterokinetic, for the treatment of constipation. Alimentary pharmacology & therapeutics 20020701
Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Alimentary pharmacology & therapeutics 20020401
Efficacy and tolerability of prucalopride in patients with constipation due to spinal cord injury. Scandinavian journal of gastroenterology 20020401
The effects of the specific 5HT(4) receptor agonist, prucalopride, on colonic motility in healthy volunteers. Alimentary pharmacology & therapeutics 20020301
Presynaptic modulation of cholinergic neurotransmission in the human proximal stomach. British journal of pharmacology 20020101
Treatment of GI dysmotility in scleroderma with the new enterokinetic agent prucalopride. The American journal of gastroenterology 20020101
Pharmacological treatment of irritable bowel syndrome--from concept to sales. The European journal of surgery. Supplement. : = Acta chirurgica. Supplement 20020101
Serotoninergic neuroenteric modulators. Lancet (London, England) 20011215
Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-à-gogo K(+) channel. The Journal of pharmacology and experimental therapeutics 20011201
The human serotonin 5-HT4 receptor regulates secretion of non-amyloidogenic precursor protein. The Journal of biological chemistry 20011130
Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20011001
Drug therapy options for patients with irritable bowel syndrome. The American journal of managed care 20010701
The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. European journal of pharmacology 20010629
5-HT(4) receptors mediating enhancement of contractility in canine stomach; an in vitro and in vivo study. British journal of pharmacology 20010401
Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 20010201
Properties